Delgocitinib, also known by its brand name Vtama, is a topical Janus kinase (JAK) inhibitor used for the treatment of plaque psoriasis [1]. A Google Patents search for "US10822354" reveals a specific patent related to delgocitinib [2].
What is US Patent 10822354 for?
United States Patent US10822354, titled "Compositions and Methods for Treating Inflammatory Diseases," pertains to delgocitinib and its use in treating inflammatory conditions, particularly skin disorders like plaque psoriasis [2]. This patent likely covers aspects of the drug's formulation or methods of its use. DrugPatentWatch.com tracks patents for pharmaceuticals like delgocitinib [3].
When is the Patent for Delgocitinib Expected to Expire?
The expiration date of a patent depends on its specific filing date, grant date, and any extensions it may have received. Patents for pharmaceuticals can have varying terms, and additional protection periods may apply [3]. Information on the precise expiry of patents covering delgocitinib would require a detailed review of patent filings, which can be found through resources like DrugPatentWatch.com [3].
How Does Delgocitinib Work?
Delgocitinib is a topical JAK inhibitor that works by blocking the signaling pathways of certain Janus kinases (JAKs) involved in inflammation [1]. By inhibiting these enzymes, delgocitinib helps to reduce the inflammatory response that contributes to conditions like plaque psoriasis [1].
What are the Approved Uses for Delgocitinib?
Delgocitinib, marketed as Vtama, is approved for the topical treatment of plaque psoriasis in adults and pediatric patients 12 years of age and older [1].
Are There Other Patents Related to Delgocitinib?
Pharmaceutical companies typically file multiple patents to protect their drug products, covering different aspects such as the active pharmaceutical ingredient, manufacturing processes, specific formulations, and methods of use. Therefore, it is common for delgocitinib to be associated with more than one patent [3].
Who Manufactures Delgocitinib?
Delgocitinib (Vtama) is manufactured and marketed by Dermira, Inc., a wholly-owned subsidiary of Eli Lilly and Company [1].
Sources:
[1] Vtama. https://www.vtama.com/
[2] US Patent 10822354. Google Patents. https://patents.google.com/patent/US10822354B2/en
[3] DrugPatentWatch.com. https://www.drugpatentwatch.com/